Full-Time

Pre-Sales Application Engineer

Confirmed live in the last 24 hours

Agilent Technologies

Agilent Technologies

10,001+ employees

eProcurement services for streamlined purchasing

No salary listed

Mid, Senior

Company Does Not Provide H1B Sponsorship

Hyderabad, Telangana, India + 2 more

More locations: Bengaluru, Karnataka, India | Bawal, India

Travel required to customer locations across India and APAC region, with 50% travel time expected.

Category
IT & Support
Software Engineering
Requirements
  • MSc/M pharm/Ph.D degree in science or equivalent (chemistry, biology, pharma or related discipline)
  • Minimum 4 years of hands-on experience on LC/LCMS, LC-QQQ, LC Q-TOF and HRMS system
  • Experience in Biopharma with expertise in LC/LCMS and HRMS
  • Strong market knowledge of biopharma/pharma
  • Excellent presentation skill along with strong communication skill is required
Responsibilities
  • Demonstrate the capabilities of Agilent LC/LCMS portfolio through sample analysis, dry demos etc
  • Provide training to Agilent users
  • Conduct Agilent user meets with the help of product specialist team
  • Develop methods and workflows focussing on Biopharma to enable our customers to utilize Agilent instruments in its full capacity
  • Conduct webinars/seminars to educate customers about Agilent’s unique capabilities
  • Understand customer’s application requirements and help PS/AMs to provide right instrument configurations
  • Work with key opinion leaders/reference customers to develop application notes/research publications/ marketing collaterals etc
  • Need to be technically strong to understand customer requirements and recommend right products.
Desired Qualifications
  • The high comfort level of interacting, discussing, and presenting to internal/external customers
  • Willingness and ability to travel to customer locations across India and APAC region

Agilent Technologies provides electronic procurement services that help businesses streamline their purchasing processes. Their main offerings include a suite of eProcurement services that allow clients to integrate their pricing into existing platforms, access a hosted catalog, and conduct transactions without paper. This system is designed to help businesses quickly find and purchase the products they need at the right price, enhancing productivity through automation and simplified workflows. Unlike many competitors, Agilent focuses on providing tailored solutions that improve connectivity and efficiency, ultimately reducing costs and increasing profitability for clients. The goal of Agilent Technologies is to support a diverse range of businesses by delivering reliable and high-quality eProcurement solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisitions like Sigsense enhance Agilent's AI capabilities in lab operations.
  • The trend towards paperless transactions boosts Agilent's service efficiency and appeal.
  • Automation in procurement is expected to increase, benefiting Agilent's offerings.

What critics are saying

  • Integration challenges from acquiring BIOVECTRA may disrupt Agilent's operations.
  • Multiple acquisitions could stretch Agilent's resources and management focus.
  • Increased competition from funded companies like RareCyte and Elegen may challenge Agilent.

What makes Agilent Technologies unique

  • Agilent offers a comprehensive suite of eProcurement services for streamlined purchasing.
  • The company focuses on automation and paperless transactions to enhance business productivity.
  • Agilent's hosted catalog and pricing integration simplify procurement processes for clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Performance Bonus

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

6%

2 year growth

5%
Business Wire
Jul 30th, 2024
Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology

Agilent has acquired Sigsense Technologies, a startup that uses artificial intelligence and power monitoring to optimize lab operations.

Biovectra
Jul 22nd, 2024
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care | BIOVECTRA

CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. The acquisition provides the ability to expand the range of [...]Read More...

Finsmes
Jun 27th, 2024
RareCyte Secures $20M Financing

RareCyte, a Seattle, WA-based Life Sciences company providing precision biology platforms including instruments, reagents, software, and services, raised $20M in funding

Business Wire
May 14th, 2024
Elegen Raises $35 Million In Series B To Accelerate Expansion Into Clinical Manufacturing

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, the leader in next-generation DNA synthesis and production, today announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron. Elegen’s current investors, including Andreessen Horowitz (a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies, also participated. The new funds will accelerate the extension of the company’s rapidly growing ENFINIA™ DNA product line across clinical workflows providing turnkey production of GMP-compliant DNA for clinical development of genetic medicines. “The age of genetic medicines is here, but these powerful modalities require innovative new manufacturing approaches to supply the critical input DNA material for rapid discovery, development and then wide-scale production,” said Matthew Hill, Ph.D., Elegen Founder and CEO. “With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and enable rapid and streamlined deployment of new clinical modalities.”

GenomeWeb
Apr 3rd, 2024
Biofidelity Raises $24M to Expand US Commercialization of Lung Cancer Test, Product Pipeline

The firm said it also plans to use the money, which brings its total raised to $60 million, to establish a dedicated manufacturing facility in the UK.